Design Therapeutics' Friedreich's ataxia data; Vincentage's obesity results from China
Plus, news about Enhertu and Tecentriq. 💪 Design Therapeutics shares Phase 1/2 data in Friedreich's ataxia: The California biotech’s DT-216P2 given at 1 mg/kg led to an average 6.4-point improvement on ...
May 18, 2026 10:56 AM EDT News Briefing Design Therapeutics' Friedreich ataxia data; Vincentage's obesity results from China ENDPOINTS Plus, news about Enhertu and Tecentriq. 💪 Design Therapeutics shares Phase 1/2 data in Friedreich ataxia: The California biotech’s DT-216P2 given at 1 mg/kg Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that